A clinical case of cardiotoxicity caused by antitumor therapy with osimertinib and bevacizumab
https://doi.org/10.17650/2782-3202-2023-3-4-48-51
Abstract
Oncological and cardiovascular diseases are the main causes of mortality worldwide. The rate of these pathologies tends to increase as the population ages. The implementation of highly effective therapeutic schemes has led to a significant increase in the survival rate of oncology patients over the last decades. In many cases, the mortality rate in oncology patients who underwent effective treatment is caused by cardiovascular events arising as a consequence of aggressive antitumor treatment or pre-existing chronic cardiovascular diseases. Among cardiovascular complications that developed both during active treatment of the malignant neoplasm and in the longer term, literature most often mentions cardiac insufficiency.
We present a clinical case of successful diagnosis and treatment of severe heart insufficiency caused by antitumor therapy with bevacizumab and osimertinib in a patient with cancer of the upper lobe of the right lung and metastases into the brain.
About the Authors
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; Department of Oncology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Bld. 2, 8 Trubetskaya St., Moscow 119991
E. V. Albitskaya
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
D. A. Chekini
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. A. Akhobekov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
Albert Amalievich Akhobekov
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
References
1. Soria J.C., Ohe Y., Vansteenkiste J. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113–25. DOI: 10.1056/NEJMoa1713137
2. Ewer M.S., Tekumalla S.H., Walding A., Atuah K.N. Cardiac safety of osimertinib: a review of data J Clin Oncol 2021;39(4):328–37. DOI: 10.1200/JCO.20.01171
3. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333(2):328–35. DOI: 10.1016/j.bbrc.2005.05.132
4. Economopoulou P., Kotsakis A., Kapiris I., Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 2015;7:133–43. DOI: 10.2147/CMAR.S77400
5. Lyon A.R., López-Fernández T., Couch L.S. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244
Review
For citations:
Zeynalova P.A., Albitskaya E.V., Chekini D.A., Akhobekov A.A. A clinical case of cardiotoxicity caused by antitumor therapy with osimertinib and bevacizumab. MD-Onco. 2023;3(4):48-51. (In Russ.) https://doi.org/10.17650/2782-3202-2023-3-4-48-51
Views:
197
Email this article 